Differential recruitment of caspase 8 to cFlip confers sensitivity or resistance to Fas-mediated apoptosis in a subset of familial lymphoma patients

Leukemia Research

Volumn 27, Issue 9, 2003, Pages 841-851

  Bäumler, Caroline ^a   Duan, Fei ^a   Onel, Kenan ^b,c   Rapaport, Beth ^c   Jhanwar, Suresh ^c   Offit, Kenneth ^c   Elkon, Keith B ^a,d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; B cell lymphoma; cFlip; Fas; p53

Indexed keywords

CASPASE 8; CELL EXTRACT; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CANCER RISK; CELL LINE; CELL SURVIVAL; CELL TRANSFORMATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FAMILIAL DISEASE; FEMALE; HUMAN; HUMAN CELL; LYMPHOMA; MALE; PRIORITY JOURNAL; REDUCTION;

EID: 0038203183     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(03)00018-3     Document Type: Article

References (48)

1. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80:1992;879-886.
2. Levine A.J., Momand J., Finlay C.A. The p53 tumour suppressor gene. Nature. 351:1991;453-456.
3. Vogelstein B., Kinzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526.
4. Krammer P.H. CD95's deadly mission in the immune system. Nature. 407:2000;789-795.
5. Drappa J., Vaishnaw A.K., Sullivan K.E., Chu J.L., Elkon K.B. Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N. Engl. J. Med. 335:1996;1643-1649.
6. Fisher G.H., Rosenberg F.J., Straus S.E., Dale J.K., Middleton L.A., Lin A.Y.et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell. 81:1995;935-946.
7. Rieux-Laucat F., Le Deist F., Hivroz C., Roberts I.A., Debatin K.M., Fischer A.et al. Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science. 268:1995;1347-1349.
8. Straus S.E., Jaffe E.S., Puck J.M., Dale J.K., Elkon K.B., Rosen-Wolff A.et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood. 98:2001;194-200.
9. Davidson W.F., Giese T., Fredrickson T.N. Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J. Exp. Med. 187:1998;1825-1838.
10. Peng S.L., Robert M.E., Hayday A.C., Craft J. A tumor-suppressor function for Fas (CD95) revealed in T cell-deficient mice. J. Exp. Med. 184:1996;1149-1154.
11. Landowski T.H., Qu N., Buyuksal I., Painter J.S., Dalton W.S. Mutations in the Fas antigen in patients with multiple myeloma. Blood. 90:1997;4266-4270.
12. Plumas J., Jacob M.C., Chaperot L., Molens J.P., Sotto J.J., Bensa J.C. Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/Apo-1)-mediated apoptosis. Blood. 91:1998;2875-2885.
13. Lamy T., Liu J.H., Landowski T.H., Dalton W.S., Loughran T.P. Jr. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3(+) large granular lymphocyte leukemia. Blood. 92:1998;4771-4777.
14. Bhatia S., Robison L.L. Epidemiology of leukemia and lymphoma. Curr. Opin. Hematol. 6:1999;201-204.
15. Lynch H.T., Marcus J.N., Lynch J.F. Genetics of Hodgkin's and non-Hodgkin's lymphoma: a review. Cancer Invest. 10:1992;247-256.
16. Siebert R., Louie D., Lacher M., Schluger A., Offit K. Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives. Leuk. Lymphoma. 27:1997;503-507.
17. Scaffidi C., Medema J.P., Krammer P.H., Peter M.E. FLICE is predominantly expressed as two functionally active isoforms, caspase-8/a and caspase-8/b. J. Biol. Chem. 272:1997;26953-26958.
18. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W.et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
19. Elkon K.B., Parnassa A.P., Foster C.L. Lupus autoantibodies target ribosomal P proteins. J. Exp. Med. 162:1985;459-471.
20. Scaffidi C., Fulda S., Srinivasan A., Friesen C., Li F., Tomaselli K.J.et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 17:1998;1675-1687.
21. Zamzami N., Marchetti P., Castedo M., Zanin C., Vayssiere J.L., Petit P.X.et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J. Exp. Med. 181:1995;1661-1672.
22. Vaishnaw A.K., Orlinick J.R., Chu J.L., Krammer P.H., Chao M.V., Elkon K.B. The molecular basis for apoptotic defects in patients with CD95 (Fas/Apo-1) mutations. J. Clin. Invest. 103:1999;355-363.
23. Dhein J., Walczak H., Bäumler C., Debatin K.M., Krammer P.H. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 373:1995;438-441.
24. Na S., Chuang T.H., Cunningham A., Turi T.G., Hanke J.H., Bokoch G.M.et al. D4-GDI, a substrate of CPP32, is proteolyzed during Fas-induced apoptosis. J. Biol. Chem. 271:1996;11209-11213.
25. Sprick M.R., Rieser E., Stahl H., Grosse-Wilde A., Weigand M.A., Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J. 21:2002;4520-4530.
26. Kischkel F.C., Lawrence D.A., Tinel A., LeBlanc H., Virmani A., Schow P.et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276:2001;46639-46646.
27. Scaffidi C., Schmitz I., Krammer P.H., Peter M.E. The role of c-FLIP in modulation of CD95-induced apoptosis. J. Biol. Chem. 274:1999;1541-1548.
28. Irmler M., Thome M., Hahne M., Schneider P., Hofmann K., Steiner V.et al. Inhibition of death receptor signals by cellular FLIP. Nature. 388:1997;190-195.
29. Wajant H., Haas E., Schwenzer R., Muhlenbeck F., Kreuz S., Schubert G.et al. Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD). J. Biol. Chem. 275:2000;24357-24366.
30. Tepper C.G., Seldin M.F. Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma. Blood. 94:1999;1727-1737.
31. Ruiz-Ruiz C., Munoz-Pinedo C., Lopez-Rivas A. Interferon-gamma treatment elevates caspase-8 expression and sensitizes human breast tumor cells to a death receptor-induced mitochondria-operated apoptotic program. Cancer Res. 60:2000;5673-5680.
32. Hahne M., Rimoldi D., Schroter M., Romero P., Schreier M., French L.E.et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science. 274:1996;1363-1366.
33. O'Connell J., Bennett M.W., O'Sullivan G.C., Collins J.K., Shanahan F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today. 20:1999;46-52.
34. Friesen C., Fulda S., Debatin K.M. Cytotoxic drugs and the CD95 pathway. Leukemia. 13:1999;1854-1858.
35. Gronbaek K., Straten P.T., Ralfkiaer E., Ahrenkiel V., Andersen M.K., Hansen N.E.et al. Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood. 92:1998;3018-3024.
36. Beltinger C., Kurz E., Bohler T., Schrappe M., Ludwig W.D., Debatin K.M. CD95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood. 91:1998;3943-3951.
37. Tamiya S., Etoh K., Suzushima H., Takatsuki K., Matsuoka M. Mutation of CD95 (Fas/Apo-1) gene in adult T-cell leukemia cells. Blood. 91:1998;3935-3942.
38. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 161:1998;2833-2840.
39. Ryu B.K., Lee M.G., Chi S.G., Kim Y.W., Park J.H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol. 194:2001;15-19.
40. Medema J.P., de Jong J., van Hall T., Melief C.J., Offringa R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190:1999;1033-1038.
41. Djerbi M., Screpanti V., Catrina A.I., Bogen B., Biberfeld P., Grandien A. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190:1999;1025-1032.
42. Roy N., Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. The c-IAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J. 16:1997;6914-6925.
43. Deveraux Q.L., Roy N., Stennicke H.R., Van Arsdale T., Zhou Q., Srinivasula S.M.et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 17:1998;2215-2223.
44. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., Baldwin A.S. Jr. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science. 281:1998;1680-1683.
45. Chun H.J., Zheng L., Ahmad M., Wang J., Speirs C.K., Siegel R.M.et al. Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature. 419:2002;395-399.
46. Teitz T., Wei T., Valentine M.B., Vanin E.F., Grenet J., Valentine V.A.et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat. Med. 6:2000;529-535.
47. Shpilberg O., Modan M., Modan B., Chetrit A., Fuchs Z., Ramot B. Familial aggregation of haematological neoplasms: a controlled study. Br. J. Haematol. 87:1994;75-80.
48. Rozenfeld-Granot G., Toren A., Amariglio N., Brok-Simoni F., Rechavi G. Mutation analysis of the FAS and TNFR apoptotic cascade genes in hematological malignancies. Exp. Hematol. 29:2001;228-233.